Targets › CALCB
2 programs from 2 companies in 6 trials: 6 Phase 3; Neurology; next expected readout Nov 2026.
CALCB/CGRP2 is a peptide hormone that induces vasodilation mediated by the CALCRL-RAMP1 receptor complex. Dilates a variety of vessels including the coronary, cerebral and systemic vasculature. (UniProt, P10092)
Open in Phaseline: the race on CALCB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Galcanezumab (LY2951742) Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Episodic Migraine; Chronic Migraine | Nov 2026 |
| H. Lundbeck | Eptinezumab Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic Headache | Mar 2027 |
Episodic Migraine (2) Chronic Migraine in Children (1) Migraine (1) Post Traumatic Headache (1) Chronic Migraine (1)
antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.